Addition of the CDK4/6 inhibitor abemaciclib to fulvestrant reduced the risk of disease progression by 45%, with an acceptable tolerability profile.
Significantly improved PFS and ORR observed with addition of lapatinib to trastuzumab plus investigator-selected aromatase inhibitor.
Pembrolizumab monotherapy was well tolerated and active in a subset of pretreated metastatic TNBC patients, with promising preliminary survival results observed in patients with CR, PR, or SD.
The addition of ipatasertib to paclitaxel improved PFS for patients with metastatic TNBC, with the greatest benefit observed in a prespecified subgroup analysis of patients with PIK3CA/AKT1/PTEN-altered tumors.
Extended intermittent letrozole did not improve DFS or other efficacy outcomes compared with continuous dosing.
TC noninferior to EC→T in patients with high-risk HER2-negative early BC with comparable 5-year DFS (90%), OS (95%), and reduced toxicity.
The addition of pembrolizumab to neoadjuvant T → AC “graduated” I-SPY 2 for efficacy, approximately tripling the estimated pCR in TNBC and in HR+/HER2- EBC.
Comparable pCR, less febrile neutropenia and LVEF decline with anthracycline-free vs anthracycline-containing neoadjuvant CT when paired with dual HER2 blockade.
Addition of veliparib and carboplatin to neoadjuvant T → AC did not increase pCR rate over carboplatin plus T → AC alone.
Review the latest developments in breast cancer care from ASCO 2017 with these expert insights from Sara Hurvitz, MD, FACP, and Kathy D. Miller, MD.
Study data showed significantly prolonged PFS and a lower rate of high-grade adverse events with olaparib monotherapy vs CT.
Pertuzumab addition significantly reduced risk of recurrence vs current standard.